A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model
Journal of Radiation Research · 2025
DOI: 10.1093/jrr/rraf035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiation Research, 2025. Verfasst von Junying Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical Univer…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, CCR5 Receptor Antagonists, Radiation Tolerance, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fujian Provincial Health Technology Project, Joint Funds for the Innovation of Science and Technology.
Abstract (Originalsprache)
Conventional fractionated radiotherapy (CFRT) for hepatocellular carcinoma (HCC) is limited by intrinsic radioresistance. In this study, we investigated the radiosensitizing potential of maraviroc, a chemokine receptor 5 (CCR5) antagonist, and its mechanistic basis in HCC. A murine HCC model was established by subcutaneous implantation of H22 cells into the hind limbs of mice. Tumor-bearing mice received CFRT with or without maraviroc, and tumor growth kinetics were evaluated. Systemic levels of myeloid-derived suppressor cells (MDSCs) in peripheral blood and plasma chemokine ligand 5 (CCL5) were longitudinally monitored post-irradiation. In vitro mechanistic studies utilized maraviroc combined with conditioned media from 2 Gy-irradiated H22 cells to dissect its radiosensitizing effects. H22 cell viability, proliferation and migration were assessed following irradiation with or without maraviroc. Flow cytometry was employed to quantify polymorphonuclear MDSC (PMN-MDSC) proliferation, differentiation and immunosuppressive capacity via T-cell proliferation assays. Compared to monotherapy with either CFRT or maraviroc alone, maraviroc combined with CFRT significantly inhibited HCC growth in the mouse model. In vitro, maraviroc did not directly enhance irradiation-induced H22 cell death or suppress proliferation but reversed PMN-MDSC-mediated immunosuppression by attenuating PMN-MDSC migration and abrogating PMN-MDSC suppression of T-cell proliferation. Maraviroc combined with CFRT significantly inhibited the differentiation of bone marrow cells into PMN-MDSCs. In conclusion, the synergistic application of CCR5 antagonist with CFRT significantly enhanced radiosensitivity in HCC, primarily through suppression of PMN-MDSCs differentiation and migration, coupled with blockade of their T-cell proliferation inhibitory functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, Fujian, China.
- National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 999 Huashan Road, Fuzhou 350212, Fujian, China.
- Department of Radiotherapy, Key Laboratory of Radiation Biology of Fujian Higher Education Institutions, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, Fujian, China.
- Department of Otolaryngology, Fujian Provincial Geriatric Hospital, 147 North Ring Middle Road, Fuzhou 350009, Fujian, China.
ORCID-Profile: Junying Chen, Jinsheng Hong
Förderung
- Fujian Provincial Health Technology Project
- Joint Funds for the Innovation of Science and Technology
Zitieren
APA
Chen, J., Lin, Q., Lan, R., Wu, J., Wang, Z., Chen, R., Huang, W., Liu, D., Yang, Y., & Hong, J. (2025). A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model. Journal of Radiation Research. https://doi.org/10.1093/jrr/rraf035
Vancouver
Chen J, Lin Q, Lan R, Wu J, Wang Z, Chen R, et al. A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model. Journal of Radiation Research. 2025. doi:10.1093/jrr/rraf035
BibTeX
@article{Chen2025,
author = {Chen, Junying and Lin, Qiaojing and Lan, Ruilong and Wu, Jiandong and Wang, Zeng and Chen, Ruiqing and Huang, Weikang and Liu, Danqing and Yang, Yunhua and Hong, Jinsheng},
title = {A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model},
journal = {Journal of Radiation Research},
year = {2025},
doi = {10.1093/jrr/rraf035}
}
EUVIMED